Growth Hormone (GH) and Adult Bone Remodeling: The Potential Use of GH in Treatment of Osteoporosis

Decreased osteoblastic activity seems to be of major importance in the pathogenesis of postmenopausal and senile osteoporosis and several lines of evidence suggest that GH may become useful in treatment of osteoporosis. GH stimulates osteoblastic proliferation and differentiation in vitro and increases production of Insulin-like Growth Factor-I and II (IGF-I and IGF-II) which both have profound stimulatory effects on osteoblasts and are important local regulators of bone remodeling. GH affects several other osteotropic hormones in vivo and increases bone turnover while the effect on bone mass is less pronounced and depends on the skeletal compartment. The few published clinical studies on the use of GH in treatment of osteoporosis have been inconclusive and well controlled studies of adequate size are greatly needed. Future research should focus on intermittent use of GH in combination with other hormones stimulating IGF production or antiresorptive agents.

[1]  L. Mosekilde,et al.  Effects of short-term growth hormone treatment on PTH, calcitriol, thyroid hormones, insulin and glucagon. , 1992, Acta endocrinologica.

[2]  S. Ljunghall,et al.  Low plasma levels of insulin‐like growth factor 1 (IGF‐1) in male patients with idiopathic osteoporosis , 1992, Journal of internal medicine.

[3]  K. Gould,et al.  Preservation of bone mass in hypogonadal female monkeys with recombinant human growth hormone administration. , 1992, The Journal of clinical endocrinology and metabolism.

[4]  K. Takaoka,et al.  Development of a monoclonal antibody specific for human bone alkaline phosphatase. , 1992, Bone and mineral.

[5]  J. Cassella,et al.  Abnormal collagen and mineral formation in osteogenesis imperfecta. , 1992, Bone and mineral.

[6]  S. Lamberts,et al.  The effects of recombinant human growth hormone (rhGH) on bone turnover and bone mass in growth hormone (GH) deficient patients , 1992 .

[7]  M. Ranke,et al.  Decreased insulin-like growth factors 1 and 2 in sera of patients with osteoporosis , 1992 .

[8]  G. Brabant,et al.  Increased bone mass with the combination therapy of hPTH(1–38) and rhGH in osteoporotic patients , 1992 .

[9]  S. Gonnelli,et al.  Human recombinant growth hormone with and without salmon calcitonin in the treatment of postmenopausal osteoporosis , 1992 .

[10]  L. Mosekilde,et al.  Effect of biosynthetic human growth hormone on biochemical markers of bone turnover — A dose response study in postmenopausal women with osteopenia , 1992 .

[11]  C. Hassager,et al.  The effect of growth hormone (GH) therapy on urinary pyridinoline cross‐links in GH‐deficient adults , 1991, Clinical endocrinology.

[12]  S. Mohan,et al.  1,25-Dihydroxyvitamin D3 differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts. , 1991, Endocrinology.

[13]  S. Duursma,et al.  Effects of recombinant human insulin-like growth factor I and II (IGF-I/-II) and growth hormone (GH) on the growth of normal adult human osteoblast-like cells and human osteogenic sarcoma cells. , 1991, Growth regulation.

[14]  L. Tatò,et al.  Effects of two different regimens of recombinant human growth hormone therapy on the bone mineral density of patients with growth hormone deficiency. , 1991, The Journal of pediatrics.

[15]  G. Rodan,et al.  Estradiol regulation of insulin-like growth factor-I expression in osteoblastic cells: evidence for transcriptional control. , 1991, Molecular endocrinology.

[16]  F. Liu,et al.  Further characterization of insulin-like-growth factor binding proteins in rat osteoblast-like cell cultures: modulation by 17 beta-estradiol and human growth hormone. , 1991, Endocrinology.

[17]  S. Mohan,et al.  Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: a potential candidate for fixing IGF-II in human bone. , 1991, Biochemical and biophysical research communications.

[18]  J. Wergedal,et al.  Insulinlike growth factor II and transforming growth factor β regulate collagen expression in human osteoblastlike cells in vitro , 1991 .

[19]  L. Mosekilde,et al.  A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  R. Eastell,et al.  Cancellous bone remodeling in type i (postmenopausal) osteoporosis: Quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  R. Marcus,et al.  Effects of short term administration of recombinant human growth hormone to elderly people. , 1990, The Journal of clinical endocrinology and metabolism.

[22]  S. Mohan,et al.  Skeletal growth factor and other growth factors known to be present in bone matrix stimulate proliferation and protein synthesis in human bone cells , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  S. Mohan,et al.  Insulin-like growth factors I and II are present in the skeletal tissues of ten vertebrates. , 1990, Metabolism: clinical and experimental.

[24]  P. Delmas,et al.  Insulin like growth factor I hormonal regulation by growth hormone and by 1,25(OH)2D3 and activity on human osteoblast-like cells in short-term cultures. , 1990, Bone.

[25]  V. Mitev,et al.  [Insulin-like growth factors]. , 1990, Eksperimentalna meditsina i morfologiia.

[26]  S. P. Chow,et al.  25-Hydroxycholecalciferol and insulin-like growth factor I are determinants of serum concentration of osteocalcin in elderly subjects with and without spinal fractures. , 1990, Bone.

[27]  Obert,et al.  Effects of human growth hormone in men over 60 years old. , 1990, The New England journal of medicine.

[28]  S. Posen,et al.  Spinal and peripheral bone mineral densities in acromegaly: the effects of excess growth hormone and hypogonadism. , 1989, Annals of internal medicine.

[29]  D. Rowe,et al.  Insulin-like growth factor I regulates type I procollagen messenger ribonucleic acid steady state levels in bone of rats. , 1989, Endocrinology.

[30]  G. Rodan,et al.  Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. , 1989, Endocrinology.

[31]  P. Marie,et al.  Osteocalcin and deoxyribonucleic acid synthesis in vitro and histomorphometric indices of bone formation in postmenopausal osteoporosis. , 1989, The Journal of clinical endocrinology and metabolism.

[32]  E. Canalis,et al.  Insulin-like growth factor (IGF) and bone. , 1989, Connective tissue research.

[33]  P Franchimont,et al.  Effects of repetitive administration of growth hormone-releasing hormone on growth hormone secretion, insulin-like growth factor I, and bone metabolism in postmenopausal women. , 1989, Acta endocrinologica.

[34]  E. Canalis,et al.  Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. , 1989, The Journal of clinical investigation.

[35]  E. Froesch,et al.  Growth hormone dependent stimulation of osteoblast-like cells in serum-free cultures via local synthesis of insulin-like growth factor I. , 1988, Biochemical and biophysical research communications.

[36]  E. Canalis,et al.  Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. , 1988, Endocrinology.

[37]  J. Aloia,et al.  Treatment of osteoporosis with calcitonin, with and without growth hormone. , 1985, Metabolism: clinical and experimental.

[38]  R L Hintz,et al.  Insulin-like growth factors I and II: aging and bone density in women. , 1984, The Journal of clinical endocrinology and metabolism.

[39]  J. Dequeker,et al.  Dynamics of growth hormone secretion in patients with osteoporosis and in patients with osteoarthrosis. , 1982, Hormone research.

[40]  F. Melsen,et al.  Iliac crest bone mass and remodelling in acromegaly. , 1981, Acta endocrinologica.

[41]  M. Kutner,et al.  Impaired growth hormone secretion in the adult population: relation to age and adiposity. , 1981, The Journal of clinical investigation.

[42]  J. Halse,et al.  Total and non-dialyzable urinary hydroxyproline in acromegalics and control subjects. , 1981, Acta endocrinologica.

[43]  R. Mazess,et al.  Bone mineral status in growth hormone deficiency. , 1980, The Journal of pediatrics.

[44]  F. Carrera,et al.  The role of growth hormone in the pathogenesis of postmenopausal osteoporosis. , 1980, Archives of Internal Medicine.

[45]  J. Aloia,et al.  Effects of growth hormone in osteoporosis. , 1976, The Journal of clinical endocrinology and metabolism.

[46]  J. Aloia,et al.  Skeletal metabolism and body composition in acromegaly. , 1972, The Journal of clinical endocrinology and metabolism.

[47]  P. Kelly,et al.  The nature of the metabolic bone disorder in acromegaly. , 1972, The Journal of laboratory and clinical medicine.